BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cold Spring Harbor Laboratory to Collaborate With Pfizer Inc. (PFE) to Speed Development of New Cancer Therapies


6/20/2012 7:44:41 AM

COLD SPRING HARBOR, N.Y.--(BUSINESS WIRE)-- Cold Spring Harbor Laboratory (CSHL) today announced a research collaboration with Pfizer Inc. (NYSE: PFE) to develop a next generation human shRNA library which could be used to silence gene expression via the process of RNA interference (RNAi) and identify new therapeutic targets in cancer.

“CSHL is pleased to partner with Pfizer to create a shRNA technology platform that could speed the validation of drug targets and open doors to new therapeutic options in a range of cancers,” said CSHL President Bruce Stillman, Ph.D.

The CSHL-Pfizer agreement will bring the Laboratory’s academic researchers together with Pfizer’s scientists in both the technology development and training environments.

“Pfizer is pleased to be involved in this partnership, which will marry cutting-edge shRNA technologies with our efforts in cancer genetics and complex tumor models toward the singular goal of identifying and validating novel targets for cancer therapeutics,” said Bob Abraham, Pfizer’s Oncology Chief Scientific Officer.

CSHL is the birthplace of the first generation shRNA library developed by HHMI Investigator and CSHL Professor Greg Hannon. Dr Hannon has pioneered the use of RNAi techniques to study mammalian genes, including development of comprehensive collections of synthetic shRNAs that can be used to specifically silence the expression of most human, mouse, and rat genes. These materials are available to the academic community.

ABOUT CSHL

Founded in 1890, Cold Spring Harbor Laboratory (CSHL) has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. CSHL is ranked number one in the world by Thomson Reuters for impact of its research in molecular biology and genetics. The Laboratory has been home to eight Nobel Prize winners. Today, CSHL's multidisciplinary scientific community is more than 350 scientists strong and its Meetings & Courses program hosts more than 11,000 scientists from around the world each year. Tens of thousands more benefit from the research, reviews, and ideas published in journals and books distributed internationally by CSHL Press. The Laboratory's education arm also includes a graduate school and programs for undergraduates as well as middle and high school students and teachers. CSHL is a private, not-for-profit institution on the north shore of Long Island. For more information, visit www.cshl.edu.

Contact:

Media:

Cold Spring Harbor Laboratory

Dagnia Zeidlickis, 516-367-8455

zeidlick@cshl.edu


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->